REACH Study: Hydroxyurea’s 7-8 Year Impact on 600 African Children with Sickle Cell Anemia
At ASH 2023, Dr. Banu Aygun, a pediatric hematologist at Cohen Children’s Medical Center in New York, shares insights from her research on hydroxyurea’s impact on children living with sickle cell anemia in sub-Saharan Africa. The study, known as REACH (Realizing Effectiveness Across Continents with Hydroxyurea), involved 600 children across four African countries who had taken hydroxyurea for 7-8 years. Watch the MEDtalk and find out more.
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.